+1 915 229 3004 (U.S.) | 
+44 7452 242832 (U.K.)
+1 915 229 3004 (U.S.) | +44 7452 242832 (U.K.)
Global Bladder Cancer Market Size was valued at USD 5.7 Billion in 2022. The Bladder Cancer market industry is projected to grow from USD 5.9 Billion in 2023 to USD 8.4 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.80% during the forecast period (2023 - 2032). The burden of bladder problems is increasing, healthcare costs are rising, and people are becoming more aware of bladder diseases and available treatments, are the key market drivers enhancing the market growth.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
The market for bladder cancer therapies and diagnostics may see significant growth as a result of rising healthcare prices, increasing healthcare spending, and the increased prevalence of bladder cancer. For instance, in an effort to raise awareness of the disease's warning signs and symptoms, the World Bladder Cancer Patient Coalition has designated March 2022 as "Don't Go Red" Month for Bladder Cancer knowledge. Improving long-term survival and quality of life requires early detection. Such actions are predicted to foster market expansion over the course of the forecast period. Additionally, the projected period's growth in the market is driven by an increase in bladder cancer incidence globally. For instance, two of the ten cancers with the greatest incidence rates worldwide, according to the Global Cancer Observatory Statistics 2020, are prostate and bladder cancer. The same source predicts that in 2020, there would most likely be 573,278 new cases of bladder cancer and 1,414,259 new cases of prostate cancer in men and women, respectively. The market is moving forward over time due to the rising incidence of cancer worldwide.
The market is also anticipated to be influenced by a variety of competing companies' tactics, including product launches and mergers and acquisitions. For instance, in August 2021, Merck, commonly known as MSD outside of the United States and Canada, announced a label update for KEYTRUDA, its anti-PD-1 drug, for first-line advanced urothelial carcinoma (bladder cancer) in the United States.
Bladder cancer is the 10th most prevalent cancer worldwide. For instance, the American Cancer Society estimates that in 2021, 83,730 Americans will be diagnosed with bladder cancer. The University of Birmingham in the UK also invested $1.18 million towards bladder cancer research centers through philanthropic donations and university investments. Another driver fueling market rise over the anticipated period is the aging population, which is more prone to bladder cancer. The elderly are more prone to urinary tract cancer because their immune systems are less able to combat malignant bladder tissue. 90% of bladder cancer patients were above the age of 55, according to a January 2021 report from the American society of clinical oncology (ASCO). According to a 2019 research from the American Cancer Society, smoking and workplace exposure can both increase the risk of developing bladder cancer. Thus, driving the Bladder Cancer market revenue.
The global Bladder Cancer market segmentation, based on Type, includes transitional cell carcinoma, invasive bladder cancer, superficial bladder cancer, adenocarcinomax, and other rare types. Transitional cell carcinoma segment dominated the global market in 2022. As a result, both developed and developing countries' healthcare infrastructure has improved. The global bladder cancer therapies market is anticipated to expand quickly during the forecast period, particularly in the superficial bladder cancer segment. Increased public awareness of superficial bladder illness, better healthcare systems in developed and developing countries, and technology improvements are all contributing factors to the growth of this market.
The global Bladder Cancer market segmentation, based on Treatment, includes chemotherapy, radiation therapy, immunotherapy, radical cystectomy, and others. The chemotherapy segment dominated the global market in 2022. This is because to the numerous chemotherapy drugs in 2021. On the other hand, the immunotherapy segment of the bladder cancer treatment market is anticipated to rise quickly. The primary factors driving the growth of the immunotherapy market are the increasing prevalence of the targeted diseases, the growing preference for immunotherapy over conventional medicines, and the growing demand for monoclonal antibodies and biosimilars.
The global Bladder Cancer market segmentation, based on Diagnosis, includes urine lab tests, cystoscopy, biopsy, imaging test, and others. Cystoscopy segment dominated the global Bladder Cancer market in 2022. During a technique known as a cystoscopy, the insides of the bladder and urethra are examined using a telescope. The urethra is used to introduce a cystoscope, a specialized endoscope, into the bladder in order to do a direct visual examination of the urothelium. Cystoscopy is inexpensive. This market sector is expanding as a result of rising cystoscopy usage, an increase in bladder cancer cases, and the introduction of new products by significant industry participants.
The global Bladder Cancer market segmentation, based on End User, includes hospital, clinic, cancer care centers, and others. The hospital segment dominated the global Bladder Cancer market in 2022. This is due to an increase in the use of technologically advanced treatment choices in hospitals around the world.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
Insights into the markets in North America, Europe, Asia-Pacific, and the rest of the world are provided by the study. The North America Bladder Cancer Market dominated this market in 2022 (45.90%). This is due to the growing R&D activity and developed healthcare infrastructure in the area. Another element that has contributed to the size and impressive growth of the bladder cancer therapeutics and diagnostics market is the existence of various biologics and biopharmaceutical companies. According to the American Cancer Society's January 2022 data, there will be around 81,180 new cases of bladder cancer in the United States year 2022 (61,700 males and 19,480 women). Therefore, it is projected that as the prevalence of bladder cancer rises, the need for bladder cancer diagnosis and treatment would increase, supporting the market's growth. Further, In the North American area, the U.S. Bladder Cancer market had the biggest market share, while the Canada Bladder Cancer market had the quickest rate of expansion.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Download Free Sample to learn more about this report
· AstraZeneca Plc.
· Bristol-Myers Squibb Company
· Celgene Corporation
· Eli Lilly and Company
· F. Hoffmann-La Roche AG
· GlaxoSmithKline Plc.
· Novartis International AG
· Pfizer Inc.
· Sanofi S.A.
· Merck & Co. Inc.
· Accord Healthcare
· Bedford Lab
July 2022: The new and less intrusive ClarityDX Bladder diagnostic test for bladder cancer has been launched by Nanostics Inc. using their ClarityDX diagnostic technology. In collaboration with DynaLIFE Medical Labs and the University of Alberta's Alberta Prostate Cancer Research Initiative (APCaRI).
· Transitional Cell Carcinoma
· Invasive Bladder Cancer
· Superficial Bladder Cancer
· Adenocarcinomax
· Other Rare Types
· Chemotherapy
· Radiation Therapy
· Immunotherapy
· Radical Cystectomy
· Others
· Urine Lab Tests
· Cystoscopy
· Biopsy
· Imaging Test
· Others
· Hospital
· Clinic
· Cancer Care Centers
· Others
· North America
- U.S.
- Canada
· Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
· Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
· Rest of the World
- Middle East
- Africa
- Latin America
|
Report Attribute/Metric |
Details |
|
Market Size 2022 |
USD 5.7 Billion |
|
Market Size 2023 |
USD 5.9 Billion |
|
Market Size 2032 |
USD 8.4 Billion |
|
Compound Annual Growth Rate (CAGR) |
4.80% (2023-2032) |
|
Base Year |
2022 |
|
Market Forecast Period |
2023-2032 |
|
Historical Data |
2018- 2022 |
|
Market Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
Type, Treatment, Diagnosis, End User, and Region |
|
Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
|
Countries Covered |
The U.S., Canada, German, France, U.K, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
|
Key Companies Profiled |
AstraZeneca Plc., Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc., Novartis International AG, Pfizer Inc., Sanofi S.A., Merck & Co. Inc., Accord Healthcare, and Bedford Lab |
|
Key Market Opportunities |
Rising influence of targeted biologics |
|
Key Market Dynamics |
The increasing awareness about bladder diseases and available therapies, growing healthcare expenditure, and the growing burden of bladder |
The global Bladder Cancer Market was valued at USD 5.7 billion in 2022, and it is estimated to reach USD 8.4 billion by 2032.
The global market is projected to grow at a CAGR of 4.80% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are AstraZeneca Plc., Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc., Novartis International AG, Pfizer Inc., Sanofi S.A., Merck & Co. Inc., Accord Healthcare, and Bedford Lab
The Transitional Cell Carcinoma Type dominated the market in 2022.
The Chemotherapy Treatment had the largest share in the global market.
Research on the market is done by industry professionals who provide personalized insights on the industry structure, market segmentation, Type assessment, competitive landscape (CL), along with penetration, and emerging trends. In addition to years of professional experience in their various fields and sectors, their analysis is largely based on primary interview (60%) and secondary research (40%) as well as years of professional experience. In addition, our researchers forecast the market's direction over the following seven years by examining past trends and the market's current position. Additionally, various trends of segments and categories that are geographically portrayed are studied and estimated using primary and secondary research.
The key level executives (VP, CEO, Marketing Directors, and Business Development Managers) of the major industry participants who are active and prominent as well as mid-scale businesses operating in this market were interviewed in-depth for this supply-side report by overall Global Market Research.
Extensive primary research was conducted to gain a deeper grasp of the market and industry. Both primary and secondary research, as well as years of pertinent professional experience, are used to support the analysis. By analyzing past and present market patterns, our experts were able to forecast the market's course over the following seven years. For the geographically offered categories in the list of market tables, it differs per category. In connection with the Global Market research report, we also conducted a number of primary interviews with senior level executives (VP, CEO's, Directors, Marketing Directors, Business Development Managers, CFOs, Technical Consultants, Key Opinion Leaders, Industry Experts, Decision Matrix Authorities, and other crucial individuals) of the key industry players who dominated the Global market.
The primary purpose of secondary research was to gather, identify, and validate the information necessary for the thorough, technical, market-focused, and commercial analysis of the global market. With the use of this study, it was also possible to classify and segment the market in accordance with market trends, geographic markets, and regional considerations linked to market type. Analysts have gathered data in the Distribution Channel for the study of the market from reliable sources including annual reports, journals, white papers, corporate presentations, company websites, international organizations of Energy and Power manufacturers, credible paid databases, and many others to gather reliable intel.
Both top-down and bottom-up methodologies were employed to assess the accuracy of the global market size. The market for as a whole was estimated using these methods for a number of different dependent submarkets. Secondary research was used to address the major industry players, and primary and secondary research was used to calculate their market shares in the various regions. This complete intellectual process includes reading the annual and financial reports of the top market participants and conducting in-depth interviews with top industry executives (VP, CEO, Marketing Directors, and Business Development Managers) to gain important industry insights.
Through reliable secondary sources and validated primary sources, the classification of the global markets and their geographic percentage splits were established. To obtain the final qualitative and quantitative data, all relevant variables that might have an impact on the market under investigation have been taken into consideration, inspected in great depth, verified through primary research, and assessed. This information was collected, added to, and thoroughly examined by professional analysts before being provided in this report. The process used to estimate the overall market size for this study is depicted in the following image as an example.
Report Code :
RL65249
Published on :
Sep 2023
Request a Free Sample Report
Speak to Analyst